Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Escitalopram→

Escitalopram Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
128196-01-0
Molecular formula
C20H21FN2O
Molecular weight
324.4 g/mol
Drug class
Selective serotonin reuptake inhibitor (SSRI)antidepressant
Mechanism of action
Selectively inhibits the serotonin transporter (SERT), reducing neuronal reuptake of serotonin and increasing serotonergic neurotransmission. Escitalopram is the S-enantiomer of citalopram; oxalate is a counter-ion in some products.
Indications / reported uses
  • Treatment of major depressive disorder in adults and adolescents where authorised
  • Treatment of generalised anxiety disorder in adults under the US product indication; other anxiety indications vary by jurisdiction

Sources: US DailyMed — Escitalopram products · NHS — Escitalopram

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Escitalopram Environmental Risk Assessment (ERA) (the Escitalopram ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.